Cizzle Bio
Cizzle Bio, with a valuation of $70.5 million, is raising funds on Dealmaker Securities. The company is revolutionizing lung cancer detection with its early detection biomarker test. Cizzle Bio’s CIZ1B biomarker test is low-cost, highly accurate, and non-invasive and is a simple blood test for lung cancer detection with 95% sensitivity. The company has a strategic partnership with Bio-Techne to leverage advanced diagnostic tools and scale Cizzle Bio’s technology. William Behnke founded Cizzle Bio in February 2024. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $4.99 million. The campaign proceeds will be used for technology and product development, licensing opportunities, sales and marketing, infrastructure, and general working capital.
Investment Overview
Raised: $0
Deal Terms
Total Commitments ($USD)
- Platform
- DealMaker Securities
- Start Date
- 11/04/2024
- Close Date
- 04/20/2025
$10,000
$5,000,000
$1,000
Equity - Common
Seed
RegCF
$0.38
$70,500,000
Company & Team
Company
- Year Founded
- 2024
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $2,500,000
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 04/20/2025 | DealMaker Securities | $70,500,000 | $0 | Equity - Common | Active | RegCF |